Clinical Trial Update: A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

View source ↗

Summary

A prospective non-interventional study evaluated Betmiga (mirabegron) in routine clinical practice for overactive bladder and urinary incontinence. The sponsor …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• Betmiga (mirabegron)

Snippet

Sponsor: Astellas Pharma Europe Ltd. | Conditions: Urgency Incontinence, Urinary Bladder Overactive | Status: COMPLETED